Semaglutide vs tirzepatide: how they really compare

Most people comparing semaglutide and tirzepatide are really asking one of a few practical questions: which one takes off more weight, which one is easier to tolerate, which is safer, and which one they can actually get and afford. This page answers those honestly, anchored to the trials that compared the two drugs directly — not cross-trial guesswork — and graded the way the rest of this site grades everything.

Two ground rules first. This page describes; it does not prescribe. It contains no doses, no titration schedules, no sourcing, and no instruction to start, stop, or switch anything — those decisions belong with the prescriber who knows your history. And “better on average” is the slipperiest phrase in this whole topic: a drug can win the average and still be the wrong choice for a given person because of tolerability, other conditions, what it’s approved for, or what a plan will cover. For the full side-effect maps, see the dedicated semaglutide side-effects and tirzepatide side-effects pages; this page is the comparison.

The short version

Here is the honest bottom line before any detail.

What’s genuinely different: tirzepatide produces more weight loss on average (shown head-to-head), and it works through a second hormone pathway (GIP) that semaglutide doesn’t touch. Tirzepatide’s label carries an oral-contraception warning semaglutide’s does not; semaglutide’s diabetes label carries a diabetic-retinopathy warning tirzepatide’s does not frame the same way. Their cardiovascular evidence differs in type. And they are approved for different specific uses.

What’s basically the same: the kind of side effects (gastrointestinal, dose-related, easing over time), the class safety warnings (boxed rodent-thyroid, pancreatitis, gallbladder, hypoglycemia only in combination), the need to plan around pregnancy and surgery, and the rebound of weight after stopping. Both are expensive brand-name medicines whose coverage varies.

	Semaglutide	Tirzepatide
Brand names	Ozempic (T2D), Wegovy (obesity), Rybelsus (oral, T2D)	Mounjaro (T2D), Zepbound (obesity, OSA)
Mechanism	GLP-1 receptor agonist	Dual GIP + GLP-1 receptor agonist
Avg. weight loss (head-to-head, obesity)	−13.7% at 72 weeks (SURMOUNT-5)	−20.2% at 72 weeks (SURMOUNT-5)
Side-effect profile	GI-dominant, dose-related	GI-dominant, dose-related — broadly similar
GI discontinuation (SURMOUNT-5)	~5.6%	~2.7%
Oral-contraception warning	No specific label warning	Yes — label-specific
Diabetic-retinopathy warning	Yes — diabetes label (from SUSTAIN-6)	Not framed the same way on label
NAION eye signal	Real but observational; in EU product info as “very rare”	Much thinner; no label warning
Cardiovascular evidence	SELECT: placebo-controlled obesity outcomes (superiority)	SURPASS-CVOT: active-comparator non-inferiority in T2D
Approved uses (US)	T2D, obesity, cardiovascular risk reduction	T2D, obesity, obstructive sleep apnea
Formulations	Injectable and oral	Injectable
Cost / access	Expensive brand drug; coverage varies	Expensive brand drug; coverage varies

Grade for the overall comparison: established for the core efficacy and profile picture (it rests on large randomized trials, including a direct head-to-head); individual specifics are graded in their own sections below.

Weight loss head-to-head: SURMOUNT-5 and SURPASS-2

This is the question most people lead with, and it’s one of the few where we have direct randomized evidence rather than comparing one trial against another.

In obesity without diabetes — SURMOUNT-5. This was the trial built to settle it: a 72-week randomized comparison of tirzepatide versus semaglutide, each titrated to its maximum tolerated dose, in 751 adults with obesity (or overweight with complications) but no diabetes. Tirzepatide came out ahead. The least-squares mean weight change was −20.2% with tirzepatide versus −13.7% with semaglutide at week 72 (about 22.8 kg versus 15.0 kg), and tirzepatide also reduced waist circumference more. The difference was statistically significant. Grade: established — a direct, randomized head-to-head of both drugs at top doses.

Tirzepatide−20.2%

Semaglutide−13.7%

Unlike cross-trial figures, this is a direct head-to-head — the same 72-week trial, both drugs at maximum tolerated dose, 751 adults with obesity and no diabetes (SURMOUNT-5). The gap was statistically significant. "More on average" still isn't "right for you."

In type 2 diabetes — SURPASS-2. Earlier, in people with type 2 diabetes, tirzepatide (at 5, 10, and 15 mg) was compared with semaglutide and produced superior reductions in both HbA1c and body weight. One honest caveat matters here: SURPASS-2 used the 1 mg dose of semaglutide — the highest approved diabetes dose at the time — not the higher doses now used for weight management. So SURPASS-2 cleanly establishes superiority for diabetes control at the doses tested, while SURMOUNT-5 is the cleaner read for the obesity-dose comparison. Grade: established, with that dosing caveat stated plainly.

The caveat that matters more than the numbers. “More on average” is a population statement, not a personal prediction. Trials report averages; they cannot tell you which individual you are. Plenty of people reach their goal on semaglutide, plenty tolerate one drug better than the other, and the right drug also depends on what you’re being treated for, your other conditions, and what you can access. A bigger average number is a reason to ask questions, not a verdict.

And a larger average number is not a personal target to chase. These are clinically supervised medicines for a medical indication — not self-directed tools for hitting a number on a scale. Anyone with a history of disordered eating should raise it with their clinician before starting and revisit it during treatment, because a medicine that turns appetite down can interact with that history in ways worth watching together; if eating starts to feel disordered or distressing, reaching out to your clinician or an eating-disorder support service is a sensible, ordinary step.

How they work: dual GIP/GLP-1 vs GLP-1 alone

Both drugs imitate gut hormones your body already makes after eating — the incretins — which nudge insulin when blood sugar is high, slow stomach emptying, and turn down appetite in the brain.

The difference is how many doors they knock on. Semaglutide is a GLP-1 receptor agonist — it mimics one incretin hormone, GLP-1. Tirzepatide is a dual agonist — it mimics two, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The plausible story is that engaging both pathways produces a larger metabolic effect, and that fits the head-to-head weight-loss result. But it’s worth resisting the tidy leap that “dual must be better for everyone.” Dual action is a reasonable mechanistic explanation for a larger average effect; it is not a guarantee for any one person, and it doesn’t exempt tirzepatide from the same safety map. Grade: the mechanism itself is established; “more pathways therefore better for you specifically” is not something the mechanism alone proves.

Side effects and tolerability: how different, really?

Honestly? Less different than the marketing energy around each drug suggests. Both are dominated by gastrointestinal effects — nausea, vomiting, diarrhea, constipation — that cluster around dose increases and ease over weeks for most people. Both share the same class warnings. The depth on each lives on the two molecule pages; here is the comparison.

The one direct tolerability datapoint comes from SURMOUNT-5: gastrointestinal adverse events leading to discontinuation were uncommon on both drugs and somewhat more frequent with semaglutide (~5.6%) than tirzepatide (~2.7%). That is a real, head-to-head finding — but read it with proportion. These are small single-digit percentages on both sides; the great majority of people in either arm did not stop for GI reasons. It would be overstating a modest difference to call one drug “well tolerated” and the other “not.” Grade: established but small — a genuine difference in a direct trial, not a chasm.

Everything else in the tolerability picture is shared in kind: fatigue, burping and reflux, hair loss tied to rapid weight loss (“Ozempic/Mounjaro face” is volume loss, not a drug toxin), some lean-mass loss alongside the larger fat loss, and injection-site reactions on the injectable forms. For any of these, the molecule pages carry the graded detail.

Tirzepatide’s oral-contraception warning

This is the clearest drug-specific difference, and it is frequently missed. Tirzepatide’s FDA label warns that it can make oral hormonal contraceptives (birth-control pills) less reliable — because the drug slows stomach emptying, and the effect is largest after starting and after each dose increase. To describe the label’s content plainly: it advises people who rely on oral contraception to either switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase, and not to stop the backup early. Semaglutide’s label does not carry this specific oral-contraceptive warning.

That is a description of what the label says — not a self-protocol to run from a web page. What’s right for any individual depends on their situation, so anyone who relies on the pill should treat this as a direct conversation with their prescriber before starting tirzepatide, not after. Grade for the difference itself: established (it is in one label and not the other). See the tirzepatide page for the fuller pregnancy-and-contraception framing, which otherwise mirrors semaglutide’s: both are stopped in pregnancy, and because both clear slowly they are planned to be stopped in advance of a planned pregnancy — not at the moment a pregnancy is discovered. Semaglutide’s label specifies discontinuing a set time before a planned conception; the exact timing is a clinician conversation for either drug.

The eye signals: NAION and diabetic retinopathy

NAION (nonarteritic anterior ischemic optic neuropathy) is a sudden, usually painless loss of vision in one eye from reduced blood flow to the optic nerve. It became a headline “GLP-1” story — but the evidence is mostly about semaglutide, not tirzepatide.

For semaglutide, a 2024 JAMA Ophthalmology study (Hathaway and colleagues, Harvard) reported a higher relative rate of NAION, and in June 2025 the EMA’s safety committee added NAION to semaglutide’s European product information as a “very rare” side effect (up to ~1 in 10,000). That signal is real, but it is observational and the absolute risk is low. For tirzepatide, the evidence is much thinner — as of mid-2026 it amounts to an FDA FAERS pharmacovigilance signal that is thin for tirzepatide, and tirzepatide’s label carries no NAION warning. Grade: observational for semaglutide and observational-but-very-limited for tirzepatide — a genuine difference in how well-characterized the signal is, not proof that either drug commonly causes it.

A second, separate eye point is semaglutide-specific and label-level. Semaglutide’s diabetes labels (based on the SUSTAIN-6 outcomes trial) warn that rapid improvement in blood glucose can be associated with a temporary worsening of diabetic retinopathy in people with type 2 diabetes who already have retinopathy. This is a labeled, semaglutide-differentiating warning that tirzepatide’s label does not frame the same way — so a diabetic reader with pre-existing retinopathy must raise it with their clinician (and eye doctor) before starting, and it can genuinely tilt the choice. Grade: label-level/established for semaglutide.

Either way, the action on the optic-nerve signal is identical: sudden vision loss or a new blind spot in one eye is a red flag — seek urgent eye care.

Cardiovascular evidence: different kinds of proof

This is a difference of type, and it’s easy to garble. Both drugs have major cardiovascular-outcomes trials, but they answer different questions.

Semaglutide has SELECT — a large (~17,600-person), placebo-controlled trial in people with overweight or obesity and established cardiovascular disease but not diabetes. It showed semaglutide reduced major cardiovascular events versus placebo — a superiority result that underpins its cardiovascular risk-reduction approval. That is the strongest kind of cardiovascular evidence: proof a drug prevents events compared with nothing.

Tirzepatide has SURPASS-CVOT (New England Journal of Medicine, December 2025) — but it was a different design: an active-comparator non-inferiority trial versus dulaglutide (another GLP-1 drug) in people with type 2 diabetes. It found tirzepatide non-inferior for three-point major cardiovascular events (hazard ratio ~0.92) and reported roughly 16% lower all-cause mortality (hazard ratio ~0.84) — though that mortality figure is a secondary finding within a non-inferiority design, so it reads as supportive and reassuring rather than as a proven mortality benefit. That is reassuring overall — it shows tirzepatide is at least as good as an established GLP-1 drug on heart outcomes — but it is not the same as a placebo-controlled superiority trial in obesity.

So the honest framing: semaglutide has placebo-controlled obesity outcomes evidence that tirzepatide does not yet have, while tirzepatide has solid active-comparator diabetes evidence. The limitation for tirzepatide is the type of trial, not the absence of one. Grade: established for both findings, with the design difference stated honestly rather than flattened into “one protects your heart and the other doesn’t.”

What each is approved for

Same molecule, different brands, different approved uses — and the approvals matter because they shape what a clinician can prescribe and what insurance will consider.

Semaglutide (US):

• Ozempic (injectable) — type 2 diabetes; also approved to reduce the risk of major cardiovascular events.
• Wegovy (injectable) — chronic weight management; also approved for cardiovascular risk reduction in people with overweight/obesity and established cardiovascular disease.
• Rybelsus (oral semaglutide tablet) — type 2 diabetes; the FDA approved an added cardiovascular risk-reduction indication for Rybelsus in October 2025.
• Oral Wegovy (oral semaglutide 25 mg) — chronic weight management, FDA approved December 2025. See each product’s current FDA label for the authoritative list of approved formulations and indications.

Tirzepatide (US):

• Mounjaro (injectable) — type 2 diabetes.
• Zepbound (injectable) — chronic weight management, and (since December 2024) moderate-to-severe obstructive sleep apnea in adults with obesity — a use tirzepatide has and semaglutide does not.

Two practical takeaways: semaglutide currently comes in both injectable and oral forms, while tirzepatide is injectable only; and the specific approved indication differs by brand, so the authoritative source for any product is its FDA label. Grade: established (regulatory fact, dated above).

Cost and access

Both are expensive brand-name medicines, and there are no generics. Beyond that, anything specific dates quickly: list prices, savings programs, and what any given plan covers all change, and they vary enormously by country, insurer, and indication (a plan may cover a drug for diabetes but not for weight management, or vice versa). For that reason this page deliberately gives no prices, no “where to get it,” and nothing about compounded or grey-market sources — that is not financial advice, not sourcing advice, and not something a web page should improvise.

What is durable to say: coverage is the single biggest practical swing factor between these two drugs for many people, and it often matters more than the head-to-head efficacy gap. The productive move is to check your specific situation and talk to your prescriber and pharmacist about what’s covered for your indication. Our coverage checker is the right starting point.

Switching between them

People switch in both directions — for tolerability, response, cost, coverage, or supply. Whether to switch, in which direction, and how to handle dosing across the change is entirely a clinician decision. The two drugs are different molecules at different dose scales, so there is no patient-facing conversion to apply, and nothing on this page should be read as a reason or a method to switch. If a switch is on your mind, that is exactly the conversation to bring to your prescriber.

The shared safety map, at a glance

Most of the safety picture is common to both drugs — same kind, same warnings — and is covered in depth on the two molecule pages. Briefly, and identically for both unless noted:

• Pregnancy & contraception — label-level/established: both are stopped in pregnancy, and because both clear slowly they are planned to be stopped in advance of a planned pregnancy rather than at the moment a pregnancy is discovered (semaglutide’s label specifies discontinuing a set time before a planned conception; the exact timing is a clinician conversation for either drug). The difference is tirzepatide’s oral-contraceptive warning (above).
• Thyroid / MEN2 — both carry the same boxed warning based on rodent thyroid C-cell tumors (human relevance not established); both are contraindicated with a personal/family history of medullary thyroid cancer or MEN 2.
• Diabetic retinopathy — label-level/established, and a semaglutide-specific point: semaglutide’s diabetes label warns that rapid blood-sugar improvement can transiently worsen pre-existing diabetic retinopathy (from SUSTAIN-6); anyone with type 2 diabetes and retinopathy should raise it before starting. Tirzepatide’s label does not frame the same warning.
• Pancreatitis — label-level/established: an uncommon-but-serious class precaution on both labels.
• Gallbladder — established class association (a 2022 meta-analysis of randomized trials found increased gallbladder/biliary disease, relative risk ~1.4), driven partly by rapid weight loss itself; on both.
• Hypoglycemia — label-level/established: low risk for either drug alone; the real risk is in combination with insulin or a sulfonylurea, which both labels warn about.
• Kidney — label-level/established: no direct toxicity; the risk is acute kidney injury secondary to dehydration from severe vomiting or diarrhea; on both.
• Surgery / anaesthesia — label-level/established (and 2024 multi-society guidance): both slow stomach emptying and can raise aspiration risk; the guidance applies to both. Tell your surgeon, anaesthetist, and prescriber well ahead.
• Gastroparesis & the lawsuits — observational: both deliberately slow gastric emptying; the “stomach paralysis” signal is observational and the litigation (which names drugs from both) is not proof of a rate or cause.
• Stopping / rebound — established for both: weight tends to return after stopping. Semaglutide’s was shown in the STEP 1 extension and STEP 4; tirzepatide’s in SURMOUNT-4 (switching to placebo led to substantial regain). This reflects obesity as a chronic condition, not a withdrawal syndrome.

For any of these, the graded depth is on the semaglutide and tirzepatide pages.

Frequently asked questions

Which is better for weight loss? On average, tirzepatide. In the direct SURMOUNT-5 obesity trial, tirzepatide produced more weight loss than semaglutide (−20.2% vs −13.7% at 72 weeks), and in SURPASS-2 it produced more weight loss and better blood-sugar control in type 2 diabetes (at the 1 mg semaglutide dose tested). That is an established, head-to-head finding. But “more on average” is not “better for you” — individual response, tolerability, your other conditions, what you’re being treated for, and what you can access all matter, and many people reach their goal on semaglutide. A larger average number is also not a personal target to chase; these are supervised medicines for a medical indication.

Which has fewer side effects? They’re broadly similar in kind — both are dominated by gastrointestinal effects that cluster around dose increases and ease over time. The one direct datapoint, from the head-to-head SURMOUNT-5 obesity trial, is that GI side effects causing people to stop were uncommon on both and somewhat more frequent with semaglutide (~5.6%) than tirzepatide (~2.7%). That’s a real difference, but a small one on both sides — not a reason to call one well-tolerated and the other not.

Is Mounjaro stronger than Ozempic? In the head-to-head SURPASS-2 diabetes trial, tirzepatide (Mounjaro) produced greater average weight loss and HbA1c reduction than semaglutide (Ozempic) at the 1 mg semaglutide dose tested, so “stronger on average” is fair for that comparison — but “stronger on average” is not “right for you,” and it doesn’t change the shared safety map. Note Mounjaro and Ozempic are the diabetes brands; the weight-management brands are Zepbound and Wegovy.

Mounjaro vs Ozempic — what’s the difference? Different molecules and different mechanisms: Mounjaro is tirzepatide (dual GIP/GLP-1); Ozempic is semaglutide (GLP-1 only). Both are approved for type 2 diabetes; both can reduce cardiovascular risk (with different supporting trials). In the head-to-head SURPASS-2 diabetes trial, tirzepatide produced greater average weight loss and HbA1c reduction than semaglutide at the 1 mg semaglutide dose tested. The side-effect profiles are broadly similar.

Zepbound vs Wegovy — what’s the difference? These are the weight-management brands: Zepbound is tirzepatide, Wegovy is semaglutide. In the head-to-head SURMOUNT-5 obesity trial, tirzepatide produced more average weight loss than semaglutide (−20.2% vs −13.7% at 72 weeks). Zepbound is also approved for obstructive sleep apnea in adults with obesity; Wegovy is approved for cardiovascular risk reduction in people with overweight/obesity and established heart disease. Which fits depends on your situation and your clinician.

Can I switch from one to the other? That’s a clinician decision, not a self-directed one. People do switch in both directions for tolerability, response, cost, coverage, or supply, but the drugs are different molecules at different dose scales — there’s no patient-facing conversion. If switching is on your mind, raise it with your prescriber.

Which is safer? Neither is clearly “safer” overall — they share the same class warnings (boxed rodent-thyroid, pancreatitis, gallbladder, hypoglycemia only in combination) and the same need to plan around pregnancy and surgery. The differences are specific: tirzepatide carries an oral-contraception warning semaglutide doesn’t, while semaglutide’s diabetes label carries a diabetic-retinopathy warning and the NAION eye signal is better characterized for semaglutide. Safety for any individual depends on their history — a clinician conversation, not a leaderboard.

Which is cheaper or easier to get covered? Both are expensive brand-name drugs with no generics, and coverage varies enormously by plan, country, and indication — a plan may cover one drug for diabetes but not for weight management. There’s no durable “cheaper” answer, and this page gives no prices or sourcing. Check your specific situation with the coverage checker and your pharmacist.

Is tirzepatide’s dual mechanism automatically better? Not for any one person. The dual GIP/GLP-1 mechanism is a plausible explanation for tirzepatide’s larger average effect, and the head-to-head data fit that. But mechanism alone doesn’t prove a given individual will do better, tolerate it better, or need it — and it doesn’t exempt the drug from the same safety map.

Does one protect the heart and the other not? Both have cardiovascular-outcomes trials, but of different types. Semaglutide has SELECT — placebo-controlled, in obesity without diabetes — showing it reduced cardiovascular events (a superiority result). Tirzepatide has SURPASS-CVOT — an active-comparator non-inferiority trial versus dulaglutide in type 2 diabetes — showing it’s at least as good as an established GLP-1 drug (with a ~16% lower all-cause mortality that is a secondary, non-inferiority-design finding, read as reassuring rather than a proven mortality benefit). The honest read: semaglutide has placebo-controlled obesity-outcomes evidence tirzepatide doesn’t yet have; tirzepatide’s limitation is the trial type, not the absence of one.

Which one is approved for what? Semaglutide: type 2 diabetes (Ozempic, Rybelsus), obesity (Wegovy and oral Wegovy), and cardiovascular risk reduction; it comes in injectable and oral forms. Tirzepatide: type 2 diabetes (Mounjaro), obesity and obstructive sleep apnea (Zepbound); injectable only. The product’s FDA label is the authoritative, current source for each.

Which should I ask my doctor for? That’s genuinely the right framing — “ask,” not “decide from a page.” Bring what matters to you (the size of the weight-loss difference, tolerability, the oral vs injectable option, whether you have sleep apnea, diabetic retinopathy, or established heart disease, and above all what’s covered) to a prescriber who knows your history. This page is a map for that conversation, not a substitute for it.

Questions to ask a clinician

• Given my goals and my health history, is there a reason to prefer one of these over the other for me specifically?
• How much does the average weight-loss difference between them actually matter for my situation?
• I take oral birth-control pills — if we consider tirzepatide, what does its contraception warning mean for me, and what would you advise?
• I have diabetic retinopathy (or another eye condition) — does semaglutide’s labeled retinopathy warning, or the NAION signal, change which drug fits and how we monitor my eyes?
• Do I have any other condition (gallbladder, pancreatitis history, thyroid/MEN2 history, a GI-motility problem) that tilts the choice?
• I have a history of disordered eating — how should we watch for appetite suppression that tips into not eating, or weight loss faster than the plan?
• Which one is covered for my indication, and what would switching mean for cost and coverage?
• If I don’t tolerate or don’t respond to one, what’s the plan — and is switching to the other reasonable?
• I have established heart disease / sleep apnea / type 2 diabetes — does that change which drug fits?
• If I could become pregnant: what contraception do you recommend, and how far in advance of trying to conceive should I stop?
• What symptoms should make me call you, and how do I reach you?
• What’s the maintenance plan, and what would make us pause, change, or stop?

Red flags / when to seek care

These red flags are the same for both drugs — the molecule you’re on doesn’t change them. Contact a clinician promptly — and for the severe versions, seek urgent care or your local emergency number — for: severe or persistent abdominal pain (especially radiating to the back with vomiting); upper-right abdominal pain, fever, or yellowing of the skin or eyes; a bloated, distended belly with vomiting and no bowel movements or gas; sudden vision loss or a new blind spot in one eye; signs of dehydration or inability to keep fluids down; symptoms of low blood sugar (especially if you also take insulin or a sulfonylurea); hives, lip or tongue swelling, or trouble breathing after a dose; a neck lump, persistent hoarseness, or trouble swallowing; and new or worsening depression or thoughts of self-harm. Separately, if eating starts to feel disordered or distressing — or weight is coming off faster than the agreed plan — that too is a reason to reach out to your clinician or an eating-disorder support service, not to push through alone.

If something feels genuinely wrong in your body, that is not a claim to grade on a ladder — it is a reason to call.